

# John-Paul Leach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8180115/publications.pdf>

Version: 2024-02-01

90  
papers

4,259  
citations

201575

27  
h-index

110317

64  
g-index

121  
all docs

121  
docs citations

121  
times ranked

2869  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of regulatory safety notices on valproate prescribing and pregnancy outcome among women of child-bearing potential in Scotland: a population-based cohort study. <i>BMJ Open</i> , 2022, 12, e058312.	0.8	4
2	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1363-1374.	6.3	93
3	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1375-1386.	6.3	104
4	Winning hearts and minds: ECG reporting in the first seizure clinic. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 364.	0.7	0
5	Measuring differential attainment: a longitudinal analysis of assessment results for 1512 medical students at four Scottish medical schools. <i>BMJ Open</i> , 2021, 11, e046056.	0.8	8
6	Epilepsy and pregnancy: identifying risks. <i>Practical Neurology</i> , 2021, , practneurol-2019-002304.	0.5	0
7	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. <i>Health Technology Assessment</i> , 2021, 25, 1-134.	1.3	11
8	Quarantining the <scp>OSCE</scp>: reflections on the Glasgow experience. <i>Clinical Teacher</i> , 2020, 17, 94-97.	0.4	3
9	Drug withdrawal in the epilepsy monitoring unit â€œ The patsalos table. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 75, 75-81.	0.9	14
10	The view of the clinician and the scientist on the family experience of sudden epilepsy deaths. <i>Epilepsy and Behavior</i> , 2020, 103, 106679.	0.9	1
11	Managing epilepsy in Ramadan: Guidance for healthcare providers and patients. <i>Epilepsy and Behavior</i> , 2020, 111, 107117.	0.9	4
12	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). <i>BMJ Open</i> , 2020, 10, e040635.	0.8	6
13	Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe. <i>Epilepsy Research</i> , 2020, 165, 106329.	0.8	13
14	Long-term mortality of patients admitted to an intensive care unit with seizures: a population-based study. <i>Anaesthesia</i> , 2020, 75, 417-418.	1.8	0
15	Refractory status epilepticus in adults admitted to ITU in Glasgow 1995â€œ2013 a longitudinal audit highlighting the need for action for provoked and unprovoked status epilepticus. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 65, 138-143.	0.9	4
16	Low serum magnesium and 1-year mortality in alcohol withdrawal syndrome. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13152.	1.7	12
17	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	0.9	13
18	Neurological Scottish neologisms. <i>Practical Neurology</i> , 2019, 19, 465-466.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Treatment of epilepsy – towards precision. F1000Research, 2018, 7, 1932.	0.8	8
20	Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. Multiple Sclerosis and Related Disorders, 2018, 24, 157-174.	0.9	12
21	Epilepsy and Pregnancy: For healthy pregnancies and happy outcomes. Suggestions for service improvements from the Multispecialty UK Epilepsy Mortality Group. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 67-72.	0.9	23
22	SUDEP, the aftermath: supporting the bereaved. Practical Neurology, 2017, 17, 489-492.	0.5	5
23	PO016 – Audit of neurological examinations in acute admissions. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A16.4-A17.	0.9	0
24	PO020 – First case of hev presenting with rhombencephalitis and gbs. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A17.4-A18.	0.9	0
25	Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. BMJ Case Reports, 2017, 2017, bcr-2017-220799.	0.2	12
26	RECURRENT MILLER FISHER SYNDROME IN ADULTS: A CASE REPORT AND LITERATURE REVIEW. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.29-e1.	0.9	0
27	RETROSPECTIVE STUDY OF STATUS EPILEPTICUS IN ADULTS IN GLASGOW FROM 1996 – 2013. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.1-e1.	0.9	1
28	After sudden unexpected death in epilepsy: Lessons learned and the road forward. Epilepsia, 2016, 57, 46-53.	2.6	22
29	Death in pregnancy: a call for neurological action. Practical Neurology, 2015, 15, 244-245.	0.5	1
30	STATUS EPILEPTICUS INCIDENCE AND PROGNOSIS 1995 – 2013. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.112-e4.	0.9	0
31	Diagnosis of loss of consciousness: When art meets science. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 495.	0.9	0
32	Time to focus on brain tumor-related epilepsy trials. Neuro-Oncology Practice, 2014, 1, 123-133.	1.0	11
33	INITIAL NEUROLOGICAL ASSESSMENT: A PILOT STUDY OF THE – GLASGOW NEUROSCREEN™. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.169-e2.	0.9	0
34	Neurology liaison services in the acute medical receiving unit. Scottish Medical Journal, 2013, 58, 234-236.	0.7	3
35	THE JOY OF TEXT; INTERACTIVE LECTURES IN THE ELECTRONIC AGE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.175-e2.	0.9	0
36	Modern management of epilepsy. Clinical Medicine, 2013, 13, 84-86.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Alcohol and drugs in epilepsy: Pathophysiology, presentation, possibilities, and prevention. <i>Epilepsia</i> , 2012, 53, 48-57.	2.6	72
38	Accelerated long-term forgetting in temporal lobe epilepsy: Verbal, nonverbal and autobiographical memory. <i>Epilepsy and Behavior</i> , 2012, 25, 622-630.	0.9	41
39	SUDEP discussions with patients and families. <i>Practical Neurology</i> , 2012, 12, 103-106.	0.5	10
40	Thinking outside of the box. <i>Practical Neurology</i> , 2011, 11, 44-47.	0.5	0
41	Seizure risk from cavernous or arteriovenous malformations. <i>Neurology</i> , 2011, 76, 1548-1554.	1.5	184
42	Can a patient-centred approach to epilepsy improve outcomes?. <i>Progress in Neurology and Psychiatry</i> , 2010, 14, 27-32.	0.4	1
43	Response to drug treatment in newly diagnosed epilepsy: A pilot study of 1H NMR- and MS-based metabonomic analysis. <i>Epilepsy Research</i> , 2010, 88, 189-195.	0.8	15
44	A new era in acute neurological consultations. <i>European Journal of Neurology</i> , 2010, 17, e26-7.	1.7	1
45	When the antiepileptic drugs are not working. <i>Practical Neurology</i> , 2009, 9, 27-32.	0.5	5
46	Overuse of the EEG. <i>Practical Neurology</i> , 2008, 8, 68-68.	0.5	0
47	Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 217-220.	0.7	45
48	Pseudostatus epilepticus in pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 97, 47-47.	1.0	4
49	The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. <i>Lancet</i> , The, 2007, 369, 1000-1015.	6.3	873
50	The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. <i>Lancet</i> , The, 2007, 369, 1016-1026.	6.3	850
51	Sodium valproate versus lamotrigine: A randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. <i>Epilepsy Research</i> , 2007, 75, 122-129.	0.8	37
52	Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1040-1042.	0.9	77
53	Asymptomatic pontine myelinolysis. <i>European Journal of Neurology</i> , 2006, 13, 1261-1263.	1.7	18
54	Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry. <i>Neurology</i> , 2006, 66, 354-360.	1.5	313

#	ARTICLE	IF	CITATIONS
55	Epilepsy in the UK: Misdiagnosis, mistreatment, and undertreatment?. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 514-520.	0.9	114
56	Levetiracetam in the management of epilepsy. British Journal of Hospital Medicine, 2004, 65, 740-744.	0.3	3
57	Occupational exposure to organic solvents and long-term nervous system damage detectable by brain imaging, neurophysiology or histopathology. Food and Chemical Toxicology, 2003, 41, 153-187.	1.8	70
58	Hallervorden and History. New England Journal of Medicine, 2003, 348, 1725-1726.	13.9	4
59	Epilepsy: time for review. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 87-89.	0.2	2
60	Success or failure with antiepileptic drug therapy. Neurology, 2003, 60, 162-163.	1.5	18
61	Remacemide for drug-resistant localization related epilepsy. The Cochrane Library, 2002, , CD001900.	1.5	7
62	Neurological presentation of Fabry's disease in a 52 year old man. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 340-342.	0.9	17
63	The legacy of vigabatrin in a regional epilepsy clinic. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 327-329.	0.9	30
64	Future Prospects for the Drug Treatment of Epilepsy. CNS Drugs, 2001, 15, 955-968.	2.7	22
65	New Antiepileptic Drugs Revolution or Marketing Spin?. Practical Neurology, 2001, 1, 70-81.	0.5	0
66	Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research, 2001, 46, 259-270.	0.8	87
67	New variant Creutzfeldt-Jakob disease presenting as localization-related epilepsy. Neurology, 2000, 54, 2188-2188.	1.5	10
68	Serial perfusion brain tomographic scans detect reversible focal ischaemia in Rasmussen's encephalitis. Postgraduate Medical Journal, 2000, 76, 33-35.	0.9	12
69	REVIEW Antiepileptic drugs: safety in numbers?. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 170-178.	0.9	15
70	Concentration-Effect Studies with Topiramate on Selected Enzymes and Intermediates of the GABA Shunt. Epilepsia, 2000, 41, S30-S34.	2.6	33
71	Lest we forgive. BMJ: British Medical Journal, 1999, 319, 459-459.	2.4	5
72	Tiagabine. Lancet, The, 1998, 351, 203-207.	6.3	93

#	ARTICLE	IF	CITATIONS
73	Study is needed of visual field defects associated with any long term antiepileptic drug. BMJ: British Medical Journal, 1998, 317, 206-206.	2.4	16
74	Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 372-376.	0.9	108
75	Polypharmacy with Anticonvulsants. CNS Drugs, 1997, 8, 366-375.	2.7	25
76	Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. European Journal of Pharmacology, 1997, 325, 35-40.	1.7	64
77	Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 179-184.	0.9	5
78	Neurochemical actions of the desglyciny metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. British Journal of Pharmacology, 1997, 121, 923-926.	2.7	7
79	Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex. General Pharmacology, 1997, 28, 715-719.	0.7	14
80	Mutual interaction between remacemide hydrochloride and phenytoin. Epilepsy Research, 1997, 26, 381-388.	0.8	14
81	Neurochemical actions of gabapentin in mouse brain. Epilepsy Research, 1997, 27, 175-180.	0.8	45
82	Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 229-234.	0.9	31
83	Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites. Epilepsia, 1996, 37, 1100-1106.	2.6	21
84	Determination of gabapentin in plasma by high-performance liquid chromatography. Biomedical Applications, 1996, 681, 421-425.	1.7	59
85	New antiepileptic drugsâ€”an explosion of activity. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 5-17.	0.9	42
86	Deliberate overdose with the novel anticonvulsant tiagabine. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 155-157.	0.9	21
87	Synergism with GABAergic drugs in refractory epilepsy. Lancet, The, 1994, 343, 1650.	6.3	40
88	Plasma Endothelinlike Immunoreactivity Levels in IDDM Patients with Microalbuminuria. Diabetes Care, 1992, 15, 1038-1040.	4.3	89
89	Free Radical Activity and Hemostatic Factors in NIDDM Patients With and Without Microalbuminuria. Diabetes, 1992, 41, 909-913.	0.3	116
90	Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes, 1992, 41, 909-913.	0.3	54